Pancreatic Cancer Clinical Trials: Resectable or Metastatic, and Why KRAS Matters

For resectable or borderline resectable cancer, treatment may be planned with surgery as a goal. Neoadjuvant trials study treatment before surgery; adjuvant trials study treatment after surgery. Perioperative studies may include treatment both before and after surgery. Locally advanced cancer cannot be removed surgically at the initial assessment, while metastatic cancer has spread to distant sites. Trials in these settings also differ by whether treatment is first-line or follows previous therapy.

A report that only says "pancreatic cancer" is not enough to judge eligibility. The protocol will name a resectability group, a line of therapy, or both.

The plain-language clinical trial glossary can help with terms such as eligibility, phase, and standard of care.

Biomarkers that actually separate one trial from another

KRAS is the most common named change. A trial may require KRAS G12D, KRAS G12C, another KRAS substitution, or any KRAS mutation. Those are not the same question.

BRCA1, BRCA2, and HRD appear in a different set of protocols, often with DNA-repair directed treatment. MSI-high or dMMR is named less often, mainly in immunotherapy studies. A trial may require one of these, exclude it, or not mention it at all.

Some of these changes have approved treatments in defined settings. Those approvals depend on the exact result, the stage, prior treatment, the test that was used, and the country where care is given. A labeled indication is not the same as limited evidence or an ongoing study.

For a current RAS-directed example, see Daraxonrasib (RASONQUE) Is Now FDA-Approved for Metastatic Pancreatic Cancer.

Recruiting pancreatic cancer trials

Questions to ask an oncologist

A short list is usually enough:

• Is this PDAC, and is it resectable, borderline resectable, locally advanced, or metastatic?
• What KRAS testing was done, and what was the exact substitution (G12D, G12C, or another)?
• Were BRCA1, BRCA2, HRD, and MSI/dMMR tested, and what were the results?
• Which treatments have already been used?
• For this resectability and biomarker profile, what is approved or considered standard where I live?
• Are there recruiting trials that match this exact profile, and how do they differ from standard care?

Want to prepare for the appointment? The guide How to Talk to Your Doctor About Clinical Trials explains how to raise the topic and what to bring with you.

Sources

• NCI: Pancreatic cancer
• NCI PDQ: Pancreatic cancer treatment (patient)
• NCI PDQ: Pancreatic cancer treatment (health professional)
• NCI: Biomarker testing for cancer treatment
• Recruiting-trial facts on this page come from ClinicalTrials.gov and are shown through TrialFinder listings.

This article was written by a patient advocate based on personal experience, not by a medical professional. It is not medical advice. Consult your doctor before making any medical decisions.